Sara S. Rinne

907 total citations
44 papers, 676 citations indexed

About

Sara S. Rinne is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sara S. Rinne has authored 44 papers receiving a total of 676 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Radiology, Nuclear Medicine and Imaging, 30 papers in Oncology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sara S. Rinne's work include Radiopharmaceutical Chemistry and Applications (28 papers), Monoclonal and Polyclonal Antibodies Research (28 papers) and HER2/EGFR in Cancer Research (15 papers). Sara S. Rinne is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (28 papers), Monoclonal and Polyclonal Antibodies Research (28 papers) and HER2/EGFR in Cancer Research (15 papers). Sara S. Rinne collaborates with scholars based in Sweden, Russia and Denmark. Sara S. Rinne's co-authors include Anna Orlova, Vladimir Tolmachev, Bogdan Mitran, Anzhelika Vorobyeva, Ayman Abouzayed, John Löfblom, Stefan Ståhl, Ulrika Rosenström, Mohamed Altai and Mats Larhed and has published in prestigious journals such as Scientific Reports, International Journal of Molecular Sciences and International Journal of Cancer.

In The Last Decade

Sara S. Rinne

41 papers receiving 676 citations

Peers

Countries citing papers authored by Sara S. Rinne

Since Specialization

Citations

This map shows the geographic impact of Sara S. Rinne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sara S. Rinne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sara S. Rinne more than expected).

Fields of papers citing papers by Sara S. Rinne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sara S. Rinne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sara S. Rinne. The network helps show where Sara S. Rinne may publish in the future.

Co-authorship network of co-authors of Sara S. Rinne

This figure shows the co-authorship network connecting the top 25 collaborators of Sara S. Rinne. A scholar is included among the top collaborators of Sara S. Rinne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sara S. Rinne. Sara S. Rinne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of targeting two antigens (GPA33 versus HER2) for ²²⁵Ac-pretargeted alpha-radioimmunotherapy of colorectal cancer 2025 ·Theranostics ·Sara S. Rinne, (unknown), Brett A. Vaughn, Sumudu Katugampola, Brian W. Miller, Darren R. Veach, Blesida Punzalan, Elisa de Stanchina, Rona Yaeger, (unknown), (unknown), Hong-Fen Guo, Jazmin Schwartz, Edward K. Fung, Roger W. Howell, Steven M. Larson, Nai‐Kong V. Cheung, Sarah M. Cheal	0
2	Affibody-Derived Drug Conjugates Targeting The Epidermal Growth Factor Receptor Are Potent And Specific Cytotoxic Agents 2025 ·ACS Pharmacology & Translational Science ·Sara S. Rinne, (unknown), Ruonan Li, (unknown), (unknown), (unknown), Stefan Ståhl, Anna Orlova, John Löfblom, Anzhelika Vorobyeva, Torbjörn Gräslund	1
3	Affibody-Drug Conjugates Targeting the Human Epidermal Growth Factor Receptor-3 Demonstrate Therapeutic Efficacy in Mice Bearing Low Expressing Xenografts 2024 ·ACS Pharmacology & Translational Science ·Jie Zhang, Sara S. Rinne, (unknown), (unknown), E. Bjorklund, Ayman Abouzayed, Stefan Ståhl, John Löfblom, Anna Orlova, Torbjörn Gräslund, Anzhelika Vorobyeva	2
4	Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors 2023 ·Cancers ·В. И. Чернов, (unknown), Roman Zelchan, (unknown), Olga Bragina, (unknown), (unknown), (unknown), Л. А. Таширева, С. В. Вторушин, Ayman Abouzayed, Sara S. Rinne, Jens Sørensen, Vladimir Tolmachev, Anna Orlova	24
5	Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model 2023 ·International Journal of Molecular Sciences ·Tianqi Xu, Alexey Schulga, Е. В. Коновалова, Sara S. Rinne, Hongchao Zhang, Olga Vorontsova, Anna Orlova, Sergey M. Deyev, Vladimir Tolmachev, Anzhelika Vorobyeva	3
6	Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation 2023 ·Cancers ·(unknown), Ayman Abouzayed, Sara S. Rinne, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Vladimir Tolmachev, Ulrika Rosenström, Anna Orlova	10
7	Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker 2023 ·Molecular Medicine Reports ·(unknown), Anzhelika Vorobyeva, (unknown), Sarah Lindbo, Tianqi Xu, Maryam Oroujeni, Sara S. Rinne, Ulrika Rosenström, Javad Garousi	0
8	Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules 2022 ·Biomedicines ·Sara S. Rinne, (unknown), (unknown), Ayman Abouzayed, (unknown), Anzhelika Vorobyeva, John Löfblom, Stefan Ståhl, Anna Orlova, Torbjörn Gräslund	5
9	Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT 2022 ·Pharmaceutics ·(unknown), (unknown), Tianqi Xu, (unknown), Anna Orlova, Maryam Oroujeni, Sara S. Rinne, Vladimir Tolmachev, Anzhelika Vorobyeva, Torbjörn Gräslund	7
10	Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1 2021 ·Cancers ·Sergey M. Deyev, Tianqi Xu, (unknown), Alexey Schulga, Е. В. Коновалова, Javad Garousi, Sara S. Rinne, (unknown), (unknown), Torbjörn Gräslund, Anna Orlova, Vladimir Tolmachev, Anzhelika Vorobyeva	12
11	66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26 2021 ·Scientific Reports ·Sara S. Rinne, Ayman Abouzayed, Katherine Gagnon, Vladimir Tolmachev, Anna Orlova	15
12	Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer 2020 ·Molecules ·Christina Baun, Bogdan Mitran, Sara S. Rinne, Johan Hygum Dam, Birgitte Brinkmann Olsen, Vladimir Tolmachev, Anna Orlova, Helge Thisgaard	9
13	On the prevention of kidney uptake of radiolabeled DARPins 2020 ·EJNMMI Research ·Mohamed Altai, Javad Garousi, Sara S. Rinne, Alexey Schulga, Sergey M. Deyev, Anzhelika Vorobyeva	23
14	Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules 2020 ·International Journal of Molecular Sciences ·Sara S. Rinne, (unknown), (unknown), Bogdan Mitran, Vladimir Tolmachev, Stefan Ståhl, John Löfblom, Anna Orlova	12
15	Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2 2019 ·International Journal of Oncology ·Anzhelika Vorobyeva, (unknown), Е. В. Коновалова, (unknown), Bogdan Mitran, Javad Garousi, Sara S. Rinne, (unknown), Anna Orlova, Sergey M. Deyev, Vladimir Tolmachev	27
16	Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake 2019 ·Scientific Reports ·Maria� Rosestedt, Karl Andersson, Sara S. Rinne, (unknown), Bogdan Mitran, Anzhelika Vorobyeva, Stefan Ståhl, John Löfblom, Vladimir Tolmachev, Anna Orlova	10
17	Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules 2019 ·Scientific Reports ·Sara S. Rinne, (unknown), (unknown), Bogdan Mitran, Ayman Abouzayed, Vladimir Tolmachev, Stefan Ståhl, John Löfblom, Anna Orlova	20
18	Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26 2019 ·Scientific Reports ·Bogdan Mitran, Helge Thisgaard, Sara S. Rinne, Johan Hygum Dam, (unknown), Vladimir Tolmachev, Anna Orlova, Ulrika Rosenström	23
19	Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model 2018 ·Theranostics ·Bogdan Mitran, (unknown), (unknown), (unknown), Ram Kumar Selvaraju, (unknown), Sara S. Rinne, Lena Claesson‐Welsh, Vladimir Tolmachev, Stefan Ståhl, Anna Orlova, John Löfblom	27
20	Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression 2017 ·International Journal of Oncology ·Maria� Rosestedt, Karl Andersson, Bogdan Mitran, Sara S. Rinne, Vladimir Tolmachev, John Löfblom, Anna Orlova, Stefan Ståhl	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact